Data Protection Privacy statement
Hobson Prior International Limited ("Hobson Prior") whose registered office is Ground Floor, Wellington Gate, 7 & 9 Church Road, Tunbridge Wells, Kent TN1 1HT and whose registration number is 04467072 (referred to as 'we', 'us' and 'our') maintains certain information and personal data concerning candidates and clients (together 'you' and 'your' shall be construed accordingly) for the purpose of providing you with the recruitment services you have requested. We respect the privacy of the personal information you provide as a user of our services and we are committed to protecting your privacy in accordance with the UK Data Protection Acts 1984 and 1998.
Hobson Prior collects, uses and disseminates the personal information you provide to us only in accordance with the policies and procedures outlined in this section.
Information we hold
Personal data we obtain and process may include CVs, application forms, results of security checks, and or credit reference checks and personal contact details including bank account details, which we maintain for administration purposes.
We obtain personal data relating to you via: -
Recruitment services that supply us with contact details relating to the recruitment industry.
All relevant information is held in manual or electronic form(such as on our database). Relevant documents may also be attached to facilitate any searches or correspondence that may be required. All phone conversations that take place are also logged in our database for reference.
How we use the information
We may use your data for the following purposes:
Advertising clients requirements and candidate's profiles on the Internet.
The data that we hold is also required to ensure the recruitment services we provide adhere to standards set by APSCo (Association of Professional Staffing Companies) and REC (Recruitment and Employment Confederation) of which we are a members.
By registering your interest with us as either a candidate of a client you agree to the following: -
Updating your information
To ensure personal data held on our database, computer and filing systems is kept up to date and accurate, we ask you to regularly update information provided to us. We rely on the accuracy of the information supplied to us and therefore request that you send an amended CV whenever this has changed.
If a candidate does not provide us with updated information for a period of 2 years, the candidate's details will, unless special circumstances apply, or as otherwise required by law, be removed from our database.
Security
All our computer systems have access restricted by password and we operate a strict firewall policy. All use of our systems and database is monitored and logged on our servers. Users of our systems and database are educated on data protection principles.
Your access to the information we hold
You have the right to request a copy of personal data held by us about you in return for a small fee. You also have the right to correct any inaccuracies contained in your personal data held by us. For further information please contact:
Data Protection Officer,
Hobson Prior International Limited
Ground Floor
Wellington Gate
7 & 9 Church Road
Tunbridge Wells
Kent TN1 1HT
The disappointing public outing for Anthera Pharmaceuticals this week, eventually listing on the Nasdaq at a 50% discount to its proposed price, was not an encouraging sign for those US companies with active IPO filings at the SEC who must now be reassessing their next financing steps.
The weakness of Anthera’s IPO – $54m raised was the lowest since Cumberland Pharmaceuticals cracked open the IPO window last August – mirrors the poor performance of Omeros since it went public in October. Anthera and Omeros are both developmental stage, high risk investment opportunities, similar to five of the six companies currently pursuing an IPO. The one mature company on the list, Prometheus Laboratories, with eight marketed products and annual profits since 2005, therefore appears the standout IPO candidate, but only if it clears up uncertainty over rights to its biggest selling product (see tables below).
Investors still risk averse
Anthera was the fifth US pharmaceutical company to go public since the broader stock market recovery in the second half of 2009.
As the table below shows, the initial optimism that IPOs would start to flow has dampened as the two most recent public offerings, Anthera and Ironwood Pharmaceuticals, have only squeezed onto the market at a significant discount to the proposed price. The average discount between the filed price and the actual list price is 20%, even after some companies had already cut back their price targets.